[24] Patients reporting meaningful change (much worse, worse, improved, much improved) were included in the responsiveness analysis to detect the ability of the PROs to measure meaningful levels of change.
Second, we did not include responsiveness analysis because of the lack of follow-up data.
Feasible and functional CRPC models for drug responsiveness analysis and the development of effective therapies targeting the FGF signaling pathway and other pathways in prostate cancer are being actively investigated.
The responsiveness analysis examined the ability of the ≥50% threshold to discriminate responders from nonresponders across clinically relevant symptoms known to be present in patients with FI.
Results are shown in table 4. Results of the responsiveness analysis.
These findings for JOQOL domain internal responsiveness were largely consistent with the results of the external responsiveness analysis.
The primary end point of the ≥50% response threshold was evaluated by validity and responsiveness analysis.
Moreover, the responsiveness analysis might have suffered from the absence of a practical clinical criterion.
Longitudinal data were available for 80.9% of the patients for the responsiveness analysis.
The NASS subscale for pain and disability (NASS-PF) was used as one of the concurrent instruments for responsiveness analysis.
